author-photo

Tak Yin Owen Tsang

10

Papers

76

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2

2021 Gut
Show All
- Source
- Cite
- Save
Citations (0)
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)

2021 Gut
Show All
- Source
- Cite
- Save
Citations (0)
Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.

2020 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (66)
O-13 : Switching from Tenofovir Disoproxil Fumarate (TDF) or Other Oral Antiviral Therapy (OAV) to Tenofovir Alafenamide (TAF) in Virally Suppressed CHB Patients with Hepatic Impairment

2020
Show All
- Source
- Cite
- Save
Citations (0)
S1126 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study

2020 The American Journal of Gastroenterology
Show All
- Source
- Cite
- Save
Citations (2)
Tenofovir alafenamide (TAF) compared with Tenofovir Dispoproxil Fumarate (TDF) in patients with chronic HBV: week 96 efficacy and safety results in Chinese patients enrolled in 2 overseas phase 3 studies

2017
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results

2017 Clinical Gastroenterology and Hepatology
Show All
- Source
- Cite
- Save
Citations (1)